arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

Neurogene Inc.

NGNE
$25.66 ▼ -2.00 (-7.23%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
15 Visible periods
25 Metrics
Peer-ranked Benchmarks
Price Chart
21
Health
Poor
Bearish
auto_awesome

Analytical Summary

Neurogene Inc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $547.2M
Dividend Yield —
Revenue Growth —
Op. Margin None
ROIC -39.0% ↘
FCF / Share $-3.67 ↗
Trailing P/E —
Price / Book 1.5x
FCF Yield —
Debt / Equity —
info Valuation on last close. End-of-day price, Nov 5, 2026.

15-Year Financial Trajectory

Annual
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$0.00
↓ -100.0% —
Net Income Profit after all expenses
$-90.35M
↓ -20.2% —
FCF / Share Free cash flow per share
$-3.67
↑ +9.6% —
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns ↑
21
Financial Health ↓
1
Cash Quality →
58

bar_chart Data from SEC EDGAR XBRL filings

Synced 5 days ago 15 years · 63 quarters